Latest News
Circassia Announces the Appointment of Pascal Hickey as Vice President, Critical Care
Circassia Ltd, a specialty biopharmaceutical company focused on controlling immune system responses, today announced the appointment of Dr Pascal Hickey as Vice President, Critical Care.
"We are very pleased with Pascal's addition to the management team at Circassia," said Steve Harris, Chief Executive Officer of Circassia. "His management experience in many different functional areas of pharmaceutical product development, and track record in managing outsourced projects means he is very well placed to deliver progress in Circassia's critical care program. I look forward to working with Pascal over the coming years as we build a world-class biopharmaceutical company."
"I am looking forward to the challenge and excitement of joining Circassia at this relatively early stage of the company's growth," said Dr Pascal Hickey. "In a short period of time Circassia has amassed an impressive product portfolio and management team. I look forward to building the value of Circassia's critical care program through rapid and efficient development over the coming year."
Pascal is a registered Pharmacist with the Pharmacy Board of Victoria, Australia, and a member of the American Association of Pharmaceutical Scientists. He brings over twelve year's international experience in the pharmaceutical development industry. Prior to joining Circassia he was General Manager of Eiffel Technologies Ltd, and then Director of Pharmaceutical Development for Biota, both listed Australian pharmaceutical companies. Earlier in his career, he held various technical, functional and project leadership roles during seven years with PowderJect Technologies, Oxford, UK. During this time he was responsible for leading a project to demonstrate systemic drug delivery in man for the first time using PowderJect's unique drug delivery technology.
21 April 2008